Nifurtimox

Edina Avdic, Pharm.D., Paul A. Pham, Pharm.D.
Nifurtimox is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Not commercially available in the U.S.
    • Available from the CDC under investigational protocols. Drug can be obtained by callingParasitic Diseases Public Inquiries (404-718-4745; e-mail chagas@cdc.gov). Outside of regular business hours call the CDC Emergency Operations Center (770-488-7100) and ask for the person on call for parasitic diseases.

NON-FDA APPROVED USES

  • American trypanosomiasis (Chagas’ disease, T. cruzi): acute early phase of the disease.
  • May be used in combination with eflornithine for the treatment of second-stage sleeping sickness.

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • Not commercially available in the U.S.
    • Available from the CDC under investigational protocols. Drug can be obtained by callingParasitic Diseases Public Inquiries (404-718-4745; e-mail chagas@cdc.gov). Outside of regular business hours call the CDC Emergency Operations Center (770-488-7100) and ask for the person on call for parasitic diseases.

NON-FDA APPROVED USES

  • American trypanosomiasis (Chagas’ disease, T. cruzi): acute early phase of the disease.
  • May be used in combination with eflornithine for the treatment of second-stage sleeping sickness.

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: June 7, 2017